CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 9, 2006--Evolved Nanomaterial Sciences (ENS), a Cambridge-based company that uses nanotechnology to revolutionize the chiral separations essential to the drug development process, recently completed a $3.3 million Series A round of financing led by Harris and Harris Group, Inc., a publicly traded venture capital firm that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS).
